Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy.

Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic rewiring. Here, we show that increased fatty acid oxidation (FAO) during prolonged BRAF inhibitor (BRAFi) treatment contributes to acquired therapy resistance in mice. Targeting FAO using the US Food and Drug Administration-approved and European Medicines Agency-approved anti-anginal drug ranolazine (RANO) delays tumour recurrence with acquired BRAFi resistance. Single-cell RNA-sequencing analysis reveals that RANO diminishes the abundance of the therapy-resistant NGFRhi neural crest stem cell subpopulation. Moreover, by rewiring the methionine salvage pathway, RANO enhances melanoma immunogenicity through increased antigen presentation and interferon signalling. Combination of RANO with anti-PD-L1 antibodies strongly improves survival by increasing antitumour immune responses. Altogether, we show that RANO increases the efficacy of targeted melanoma therapy through its effects on FAO and the methionine salvage pathway. Importantly, our study suggests that RANO could sensitize BRAFi-resistant tumours to immunotherapy. Since RANO has very mild side-effects, it might constitute a therapeutic option to improve the two main strategies currently used to treat metastatic melanoma.

BARS Influences Neuronal Development by Regulation of Post-Golgi Trafficking.

Neurons are highly polarized cells requiring precise regulation of trafficking and targeting of membrane proteins to generate and maintain different and specialized compartments, such as axons and dendrites. Disruption of the Golgi apparatus (GA) secretory pathway in developing neurons alters axon/dendritic formation. Therefore, detailed knowledge of the mechanisms underlying vesicles exiting from the GA is crucial for understanding neuronal polarity. In this study, we analyzed the role of Brefeldin A-Ribosylated Substrate (CtBP1-S/BARS), a member of the C-terminal-binding protein family, in the regulation of neuronal morphological polarization and the exit of membrane proteins from the Trans Golgi Network. Here, we show that BARS is expressed during neuronal development in vitro and that RNAi suppression of BARS inhibits axonal and dendritic elongation in hippocampal neuronal cultures as well as largely perturbed neuronal migration and multipolar-to-bipolar transition during cortical development in situ. In addition, using plasma membrane (PM) proteins fused to GFP and engineered with reversible aggregation domains, we observed that expression of fission dominant-negative BARS delays the exit of dendritic and axonal membrane protein-containing carriers from the GA. Taken together, these data provide the first set of evidence suggesting a role for BARS in neuronal development by regulating post-Golgi membrane trafficking.

Mecanismos fisiopatológicos del hipotiroidismo en la infertilidad femenina / Physiopathological mechanisms of hypothyroidism on feminine infertility

INTRODUCCIÓN Y OBJETIVO: El hipotiroidismo es una condición frecuente en mujeres en Chile. Existe evidencia contundente de una fuerte asociación entre esta patología e infertilidad femenina. El objetivo de esta revisión es resumir los principales mecanismos fisiopatológicos descritos en la literatura que explicarían la infertilidad femenina en mujeres hipotiroideas. MÉTODOS: Se llevó a cabo una búsqueda bibliográfica por medio PubMed con los términos: hipotiroidismo, infertilidad y fisiopatología. De todos los artículos se seleccionaron únicamente los correspondientes a población femenina. Incluimos tanto hipotiroidismo clínico como subclínico, y mujeres eutiroideas con anti-TPO (+). RESULTADOS: Clasificamos la literatura disponible en tres grupos de mecanismo fisiopatológicos. En primer lugar, la deficiencia de hormonas tiroideas T3 y T4 producirían alteraciones en la foliculogénesis, ovulación, implantación y placentación. En segundo lugar, la hiperprolactinemia secundaria al hipotiroidismo llevaría a un hipogonadismo hipogonadotrópico e insuficiencia en la fase lútea. En tercer lugar, los anticuerpos anti-TPO, independientemente de los niveles de hormonas tiroideas, podrían tener una reacción cruzada con proteínas presentes en el útero, afectando el proceso de implantación. CONCLUSIONES: El hipotiroidismo produce infertilidad femenina por variados mecanismos fisiopatológicos. Dada la variabilidad de estos, existe un mayor espectro de aproximaciones terapéuticas para tratar mujeres hipotiroideas con problemas de fertilidad.

INTRODUCTION AND OBJECTIVE: Hypothyroidism is a frequent condition in Chile in women in Chile. There is strong evidence of an association between this pathology and feminine infertility. The objective of this review is to summarize the main physiopathological mechanisms described in the literature that explain infertility in women with hypothyroidism. METHODS: We performed a bibliographic search on PubMed with the terms: hypothyroidism, infertility, physiopathology. Among all the articles we selected only the ones regarding to feminine population. We included both clinical and subclinical hypothyroidism, and euthyroid women with Anti-TPO (+). RESULTS: We classified the available literature into three groups of physiological mechanisms. In the first place, decreased thyroid hormones T3 and T4 may lead to alterations on folliculogenesis, ovulation, implantation and placentation. Secondly, hyperprolactinemia secondary to hypothyroidism would produce hypogonadotropic hypogonadism and luteal phase insufficiency. Thirdly, anti-TPO antibodies, independently on thyroid hormones levels, may have a cross reactivity towards proteins in the womb, negatively affecting the process of implantation. CONCLUSIONS: Hypothyroidism produces infertility through varied physiopathological mechanisms. Due to their variability, there is a wider scope for therapeutical approaches to treat women with hypothyroidism and fertility problems.

Safety profile of biological intravenous therapy in a rheumatoid arthritis patients cohort. Clinical nursing monitoring (Sebiol study).

INTRODUCTION: The Biologics used in the management of rheumatoid arthritis (RA) in recent years, have comprehensively permitted to understand its security, as shown in registries such as BIOBADASER. The present manuscript represents an observational cohort study to describe the safety perinfusional profile of those intravenous treatments. OBJECTIVES: To confirm the safety profile of biological therapies in routine clinical practice, after the administration of intravenous drugs and 24 hours post-administration. MATERIAL AND METHODS: We evaluated a cross-sectional cohort of 114 patients with RA (according to the American College of Rheumatology ACR criteria), attending within one month in 2009 the nursing clinics of day care hospital of 12 Catalonian hospitals. All patients were treated with intravenous biological agents. We recorded the age, sex, current and previous drug treatments, we also collected data about previous vaccination and premedication received and any adverse event occurring at the time of drug administration or within 24 hours. If an adverse event occurred, was categorized by MedDRAv11.0 International Dictionary, and categorized in terms of intensity (mild, moderate, severe), relationship to drug administration according to Karch and Lasagna algorithm (unrelated, unlikely, possible, probable, definite) and the further measures taken. RESULTS: 111 patients met the inclusion criteria, with a mean age of 56.06 years (SD: 12.12), 90 of them women (81.1%) and mean time since diagnosis of the disease of 11.97 years (SD: 7.95). 24 patients (21.6%) had a history of allergy. 12 adverse events were observed in 7 patients, 9 of which at the time of administration and 3 in 24 hours after. There were no serious adverse events and only one of the adverse events (AEs) was rated as moderate (urticaria). The remaining AA were mild.